Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1984;64:459-464
© 1984 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DEMETRIOU, E.
Right arrow Articles by CRIGLER, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DEMETRIOU, E.
Right arrow Articles by CRIGLER, J. F., Jr

Final Height in Estrogen-Treated Patients With Turner Syndrome

EFSTRATIOS DEMETRIOU, MD, S JEAN EMANS, MD and JOHN F. CRIGLER, Jr, MD

From the Division of Adolescent/Young Adult Medicine and Endocrinology, Department of Medicine, The Children's Hospital Medical Center, and the Department of Pediatrics, Harvard Medical School, Boston, Massachusetts; and the Section of Adolescent Medicine, Children's Memorial Hospital, and the Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Abstract

The growth effects of estrogen therapy in 37 adolescent girls with gonadal dysgenesis associated with various X chromosomal abnormalities were investigated. Nineteen patients (group 1) were treated at a mean of 14.3 years, and 18 patients (group 2) were treated at an average of 17.2 years. Final height was independent of the age estrogen therapy was initiated. Nevertheless, the growth responses to estrogens of groups 1 and 2 were different. For group 1, growth velocity significantly increased from 3.0 to 4.2 cm per year over the first year of therapy; for group 2, the corresponding velocities were not significantly different. Mean midparental height was significantly correlated with final height; however, karyotype, estrogen dosage, and duration of therapy were not significantly related to final height. The authors conclude that earlier estrogen therapy alone for patients with gonadal dysgenesis does not significantly compromise final height and produces development more in keeping with their normal adolescent peers.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by the American College of Obstetricians and Gynecologists.